Pia Österlund

Om mig
Publikationer
Populärvetenskap och samverkan

Om mig

Adjungerad professor i kolorektalcancer vid institutionen för
onkologi-patologi från 1 februari 2021. Primär anställning: Läkare vid
Karolinska Universitetssjukhuset respektive Tampere Universitetssjukhus. För
mer information, se den engelska profilsidan.

Artiklar

Article: CANCERS. 2024;16(5):1052

Impact of Primary Tumor Location on Demographics, Resectability, Outcomes, and Quality of Life in Finnish Metastatic Colorectal Cancer Patients (Subgroup Analysis of the RAXO Study).

Aho S; Osterlund E; Ristimäki A; Nieminen L; Sundström J; Mäkinen MJ; Kuopio T; Kytölä S; Ålgars A; Ristamäki R; Heervä E; Kallio R; Halonen P; Soveri L-M; Nordin A; Uutela A; Salminen T; Stedt H; Lamminmäki A; Muhonen T; Kononen J; Glimelius B; Isoniemi H; Lehto JT; Lehtomäki K; Osterlund P
Article: INTERNATIONAL JOURNAL OF CANCER. 2024;154(3):488-503

Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts.

Osterlund E; Ristimäki A; Mäkinen MJ; Kytölä S; Kononen J; Pfeiffer P; Soveri L-M; Keinänen M; Sorbye H; Nunes L; Salminen T; Nieminen L; Uutela A; Halonen P; Ålgars A; Sundström J; Kallio R; Ristamäki R; Lamminmäki A; Stedt H; Heervä E; Kuopio T; Sjöblom T; Isoniemi H; Glimelius B; Osterlund P
Article: CLINICAL NUTRITION ESPEN. 2023;57:364-374

Time to act! - A cross-sectional study on how nutritional risk increases during hospitalization and associates with worse outcome.

Orell H; Pohju A; Tuokkola J; Junttila K; Heikkilä A; Österlund P; Schwab U; Mäkitie A
Article: BRITISH JOURNAL OF SURGERY. 2023;110(8):931-935

Resectability and resection rates of colorectal liver metastases according to RAS and BRAF mutational status: prospective study.

Uutela A; Nordin A; Osterlund E; Halonen P; Kallio R; Soveri L-M; Salminen T; Ålgars A; Ristimäki A; Ovissi A; Lamminmäki A; Muhonen T; Kononen J; Ristamäki R; Heervä E; Stedt H; Lehtomäki K; Kytölä S; Sundström J; Mäkinen MJ; Nieminen L; Kuopio T; Keinänen M; Osterlund P; Isoniemi H; RAXO Study Group
Article: CANCERS. 2023;15(13):3398

Association between Computed Tomography-Determined Loss of Muscle Mass and Impaired Three-Month Survival in Frail Older Adults with Cancer.

Tolonen A; Kerminen H; Lehtomäki K; Huhtala H; Bärlund M; Österlund P; Arponen O
Article: JOURNAL OF CLINICAL MEDICINE. 2023;12(10):3541

Resectability, Resections, Survival Outcomes, and Quality of Life in Older Adult Patients with Metastatic Colorectal Cancer (the RAXO-Study).

Lehtomäki K; Soveri L-M; Osterlund E; Lamminmäki A; Uutela A; Heervä E; Halonen P; Stedt H; Aho S; Muhonen T; Ålgars A; Salminen T; Kallio R; Nordin A; Aroviita L; Nyandoto P; Kononen J; Glimelius B; Ristamäki R; Isoniemi H; Osterlund P
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023;24(7):6753

Transient Changes in Serum CEA, CA19-9, CRP, YKL-40, and IL-6 during Adjuvant Chemotherapy and Survival of Patients with Colorectal Cancer.

Lehtomäki K; Heervä E; Kellokumpu-Lehtinen P-L; Mustonen H; Salminen T; Joensuu H; Hermunen K; Boisen MK; Johansen JS; Haglund C; Osterlund P
Article: ESMO OPEN. 2023;8(2):101199

Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer.

Punt CJA; Heinemann V; Maughan T; Cremolini C; Van Cutsem E; McDermott R; Bodoky G; André T; Osterlund P; Teske AJ; Pfeiffer P
Article: JOURNAL OF GERIATRIC ONCOLOGY. 2023;14(1):101408

Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy - The randomized NORDIC9-study.

Liposits G; Ryg J; Skuladottir H; Winther SB; Möller S; Hofsli E; Shah C-H; Poulsen LØ; Berglund Å; Qvortrup C; Osterlund P; Glimelius B; Sorbye H; Pfeiffer P
Article: ANNALS OF ONCOLOGY. 2023;34(1):10-32

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Cervantes A; Adam R; Roselló S; Arnold D; Normanno N; Taïeb J; Seligmann J; De Baere T; Osterlund P; Yoshino T; Martinelli E; ESMO Guidelines Committee. Electronic address: cli
Article: CANCERS. 2022;14(24):6238

Associations between Response to Commonly Used Neo-Adjuvant Schedules in Rectal Cancer and Routinely Collected Clinical and Imaging Parameters.

Karimi M; Osterlund P; Hammarström K; Imam I; Frodin J-E; Glimelius B
Article: JOURNAL OF CLINICAL MEDICINE. 2022;11(19):5603

The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study.

Liposits G; Skuladottir H; Ryg J; Winther SB; Möller S; Hofsli E; Shah C-H; Poulsen LØ; Berglund Å; Qvortrup C; Osterlund P; Johansen JS; Glimelius B; Sorbye H; Pfeiffer P
Article: BRITISH JOURNAL OF CANCER. 2022;127(4):686-694

Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study.

Uutela A; Osterlund E; Halonen P; Kallio R; Ålgars A; Salminen T; Lamminmäki A; Soveri L-M; Ristamäki R; Lehtomäki K; Stedt H; Heervä E; Muhonen T; Kononen J; Nordin A; Ovissi A; Kytölä S; Keinänen M; Sundström J; Nieminen L; Mäkinen MJ; Kuopio T; Ristimäki A; Isoniemi H; Osterlund P
Article: HEALTHCARE. 2022;10(9):1618

How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?

Horgan D; Baird A-M; Middleton M; Mihaylova Z; Van Meerbeeck JP; Vogel-Claussen J; Van Schil PE; Malvehy J; Ascierto PA; Dube F; Zaiac M; Lal JA; Kamińska-Winciorek G; Donia M; André T; Kozaric M; Osterlund P; Dumitrascu DL; Bertolaccini L
Article: ESMO OPEN. 2022;7(3):100427

Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study.

Osterlund P; Kinos S; Pfeiffer P; Salminen T; Kwakman JJM; Frödin J-E; Shah CH; Sorbye H; Ristamäki R; Halonen P; Soveri LM; Heervä E; Ålgars A; Bärlund M; Hagman H; McDermott R; O'Reilly M; Röckert R; Liposits G; Kallio R; Flygare P; Teske AJ; van Werkhoven E; Punt CJA; Glimelius B
Article: CANCERS. 2022;14(7):1713

Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-Study.

Lehtomäki K; Stedt HP; Osterlund E; Muhonen T; Soveri L-M; Halonen P; Salminen TK; Kononen J; Kallio R; Ålgars A; Heervä E; Lamminmäki A; Uutela A; Nordin A; Lehto J; Saarto T; Sintonen H; Kellokumpu-Lehtinen P-L; Ristamäki R; Glimelius B; Isoniemi H; Osterlund P
Article: CANCER TREATMENT AND RESEARCH COMMUNICATIONS. 2022;31:100517

Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer.

Falk P; Severin M; Berglund Å; Guren MG; Hofsli E; Österlund P; Tandberg A; Eberhard J; Sorbye H
Article: FRONTIERS IN ONCOLOGY. 2022;12:826073

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer.

Osterlund E; Ristimäki A; Kytölä S; Kuopio T; Heervä E; Muhonen T; Halonen P; Kallio R; Soveri L-M; Sundström J; Keinänen M; Ålgars A; Ristamäki R; Sorbye H; Pfeiffer P; Nunes L; Salminen T; Lamminmäki A; Mäkinen MJ; Sjöblom T; Isoniemi H; Glimelius B; Osterlund P
Article: FRONTIERS IN NUTRITION. 2022;9:1030619

GLIM in diagnosing malnutrition and predicting outcome in ambulatory patients with head and neck cancer.

Orell HK; Pohju AK; Osterlund P; Schwab US; Ravasco P; Mäkitie A
Article: ESMO OPEN. 2021;6(6):100219

Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global survey.

Cufer T; Kosty M; Osterlund P; Jezdic S; Pyle D; Awada A; Close J; El-Saghir N; Lordick F; Rutkowski P; Tfayli A; Wildiers H
Article: CANCERS. 2021;13(15):3892

Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer.

Lehtomäki K; Mustonen H; Kellokumpu-Lehtinen P-L; Joensuu H; Hermunen K; Soveri L-M; Boisen MK; Dehlendorff C; Johansen JS; Haglund C; Osterlund P
Article: ESMO OPEN. 2021;6(4):100208

Treatment response of colorectal cancer liver metastases to neoadjuvant or conversion therapy: a prospective multicentre follow-up study using MRI, diffusion-weighted imaging and 1H-MR spectroscopy compared with histology (subgroup in the RAXO trial).

Uutela A; Ovissi A; Hakkarainen A; Ristimäki A; Lundbom N; Kallio R; Soveri LM; Salminen T; Ålgars A; Halonen P; Ristamäki R; Nordin A; Blanco Sequeiros R; Rinta-Kiikka I; Lantto E; Virtanen J; Pääkkö E; Liukkonen E; Saunavaara J; Ryymin P; Lammentausta E; Osterlund P; Isoniemi H; RAXO Study Group
Article: BRITISH JOURNAL OF SURGERY. 2021;108(7):817-825

Centralized repeated resectability assessment of patients with colorectal liver metastases during first-line treatment: prospective study.

Isoniemi H; Uutela A; Nordin A; Lantto E; Kellokumpu I; Ovissi A; Kosunen J; Kallio R; Soveri LM; Salminen T; Ålgars A; Lamminmäki A; Halonen P; Ristamäki R; Räsänen J; Karjula H; Vaalavuo Y; Lavonius M; Osterlund P
Article: JCO ONCOLOGY PRACTICE. 2021;17(7):442-e998

Nutrition in Cancer Care: A Brief, Practical Guide With a Focus on Clinical Practice

Liposits G; Orrevall Y; Kaasa S; Osterlund P; Cederholm T
Article: CANCERS. 2021;13(11):2604

Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study.

Liposits G; Eshøj HR; Möller S; Winther SB; Skuladottir H; Ryg J; Hofsli E; Shah C-H; Poulsen LØ; Berglund Å; Qvortrup C; Österlund P; Glimelius B; Sorbye H; Pfeiffer P
Article: THE LANCET REGIONAL HEALTH - EUROPE. 2021;3:100049

Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention study.

Osterlund P; Salminen T; Soveri L-M; Kallio R; Kellokumpu I; Lamminmäki A; Halonen P; Ristamäki R; Lantto E; Uutela A; Osterlund E; Ovissi A; Nordin A; Heervä E; Lehtomäki K; Räsänen J; Murashev M; Aroviita L; Jekunen A; Lindvall-Andersson R; Nyandoto P; Kononen J; Lepistö A; Poussa T; Muhonen T; Ålgars A; Isoniemi H; Members of The RAXO study group are collaborators
Article: ACTA ONCOLOGICA. 2020;59(12):1416-1423

Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer.

Hermunen K; Soveri L-M; Boisen MK; Mustonen HK; Dehlendorff C; Haglund CH; Johansen JS; Osterlund P
Article: NUTRIENTS. 2020;12(2):E407-407

Consumption of Lactose, Other FODMAPs and Diarrhoea during Adjuvant 5-Fluorouracil Chemotherapy for Colorectal Cancer.

Holma R; Laatikainen R; Orell H; Joensuu H; Peuhkuri K; Poussa T; Korpela R; Österlund P
Article: ANNALS OF ONCOLOGY. 2020;31(2):246-256

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group.

André T; Vernerey D; Im SA; Bodoky G; Buzzoni R; Reingold S; Rivera F; McKendrick J; Scheithauer W; Ravit G; Fountzilas G; Yong WP; Isaacs R; Österlund P; Liang JT; Creemers GJ; Rakez M; Van Cutsem E; Cunningham D; Tabernero J; de Gramont A
Article: PLOS ONE. 2020;15(12):e0243900

PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3.

Ali AS; Langer SW; Federspiel B; Hjortland GO; Grønbæk H; Ladekarl M; Welin S; Weber Vestermark L; Arola J; Osterlund P; Knigge U; Sørbye H; Micke P; Grimelius L; Grönberg M; Tiensuu Janson E
Article: PLOS ONE. 2020;15(11):e0239819

Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing.

Holm M; Andersson E; Osterlund E; Ovissi A; Soveri L-M; Anttonen A-K; Kytölä S; Aittomäki K; Osterlund P; Ristimäki A
Article: PLOS ONE. 2020;15(8):e0236569

Elevated serum YKL-40, IL-6, CRP, CEA, and CA19-9 combined as a prognostic biomarker panel after resection of colorectal liver metastases.

Peltonen R; Gramkow MH; Dehlendorff C; Osterlund PJ; Johansen JS; Isoniemi H
Article: SCANDINAVIAN JOURNAL OF SURGERY. 2019;108(3):201-209

Histologically Verified Biliary Invasion was Associated with Impaired Liver Recurrence-Free Survival in Resected Colorectal Cancer Liver Metastases.

Reijonen P; Österlund P; Isoniemi H; Arola J; Nordin A
Article: TRANSLATIONAL ONCOLOGY. 2019;12(8):1122-1130

Two-Week Aflibercept or Erlotinib Administration Does Not Induce Changes in Intestinal Morphology in Male Sprague-Dawley Rats But Aflibercept Affects Serum and Urine Metabolic Profiles.

Forsgård RA; Marrachelli VG; Lindén J; Frias R; Collado MC; Korpela R; Monleon D; Spillmann T; Österlund P
Article: LANCET GASTROENTEROLOGY & HEPATOLOGY. 2019;4(5):376-388

Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial.

Winther SB; Liposits G; Skuladottir H; Hofsli E; Shah C-H; Poulsen LØ; Ryg J; Osterlund P; Berglund Å; Qvortrup C; Glimelius B; Sorbye H; Pfeiffer P
Article: ACTA ONCOLOGICA. 2019;58(4):398-406

Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy.

Soveri LM; Lamminmäki A; Hänninen UA; Karhunen M; Bono P; Osterlund P
Article: FRONTIERS IN NUTRITION. 2019;6:22

Nutritional Counseling for Head and Neck Cancer Patients Undergoing (Chemo) Radiotherapy-A Prospective Randomized Trial.

Orell H; Schwab U; Saarilahti K; Österlund P; Ravasco P; Mäkitie A
Article: ACTA ONCOLOGICA. 2018;57(6):750-758

Can carcinoembryonic antigen replace computed tomography in response evaluation of metastatic colorectal cancer?

Hermunen K; Lantto E; Poussa T; Haglund C; Österlund P
Article: MEDICAL ONCOLOGY. 2018;35(4):47

Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3).

Ali AS; Grönberg M; Langer SW; Ladekarl M; Hjortland GO; Vestermark LW; Österlund P; Welin S; Grønbæk H; Knigge U; Sorbye H; Janson ET
Article: TUMOR BIOLOGY. 2018;40(1):1010428317752944-101042831775294

Postoperative CEA is a better prognostic marker than CA19-9, hCGβ or TATI after resection of colorectal liver metastases.

Peltonen R; Österlund P; Lempinen M; Nordin A; Stenman U-H; Isoniemi H
Article: EJSO. 2017;43(9):1682-1689

Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.

Galleberg RB; Knigge U; Tiensuu Janson E; Vestermark LW; Haugvik S-P; Ladekarl M; Langer SW; Grønbæk H; Österlund P; Hjortland GO; Assmus J; Tang L; Perren A; Sorbye H
Article: BMC CANCER. 2017;17(1):548

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.

Winther SB; Österlund P; Berglund Å; Glimelius B; Qvortrup C; Sorbye H; Pfeiffer P; - on behalf of the Academy of Geriatric Cancer Res
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2017;80(2):317-332

Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague-Dawley rats.

Forsgård RA; Marrachelli VG; Korpela K; Frias R; Collado MC; Korpela R; Monleon D; Spillmann T; Österlund P
Article: ACTA OTO-LARYNGOLOGICA. 2017;137(7):778-785

Cachexia at diagnosis is associated with poor survival in head and neck cancer patients.

Orell-Kotikangas H; Österlund P; Mäkitie O; Saarilahti K; Ravasco P; Schwab U; Mäkitie AA
Article: BRITISH JOURNAL OF CANCER. 2017;116(10):1271-1278

Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.

Guren TK; Thomsen M; Kure EH; Sorbye H; Glimelius B; Pfeiffer P; Österlund P; Sigurdsson F; Lothe IMB; Dalsgaard AM; Skovlund E; Christoffersen T; Tveit KM
Article: INTERNATIONAL JOURNAL OF CANCER. 2017;140(4):922-929

EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.

Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
Article: PLOS ONE. 2017;12(11):e0187667

Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma.

Ali AS; Grönberg M; Federspiel B; Scoazec J-Y; Hjortland GO; Grønbæk H; Ladekarl M; Langer SW; Welin S; Vestermark LW; Arola J; Österlund P; Knigge U; Sorbye H; Grimelius L; Janson ET
Article: NEUROLOGY. 2016;87(22):2290-2299

FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders.

Lehtonen JM; Forsström S; Bottani E; Viscomi C; Baris OR; Isoniemi H; Höckerstedt K; Österlund P; Hurme M; Jylhävä J; Leppä S; Markkula R; Heliö T; Mombelli G; Uusimaa J; Laaksonen R; Laaksovirta H; Auranen M; Zeviani M; Smeitink J; Wiesner RJ; Nakada K; Isohanni P; Suomalainen A
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2016;78(4):863-874

Intestinal permeability to iohexol as an in vivo marker of chemotherapy-induced gastrointestinal toxicity in Sprague-Dawley rats.

Forsgård RA; Korpela R; Holma R; Lindén J; Frias R; Spillmann T; Österlund P
Article: ANNALS OF ONCOLOGY. 2016;27(8):1386-1422

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Van Cutsem E; Cervantes A; Adam R; Sobrero A; Van Krieken JH; Aderka D; Aranda Aguilar E; Bardelli A; Benson A; Bodoky G; Ciardiello F; D'Hoore A; Diaz-Rubio E; Douillard J-Y; Ducreux M; Falcone A; Grothey A; Gruenberger T; Haustermans K; Heinemann V; Hoff P; Köhne C-H; Labianca R; Laurent-Puig P; Ma B; Maughan T; Muro K; Normanno N; Österlund P; Oyen WJG; Papamichael D; Pentheroudakis G; Pfeiffer P; Price TJ; Punt C; Ricke J; Roth A; Salazar R; Scheithauer W; Schmoll HJ; Tabernero J; Taïeb J; Tejpar S; Wasan H; Yoshino T; Zaanan A; Arnold D
Article: ANNALS OF SURGICAL ONCOLOGY. 2016;23(5):1721-1728

Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study.

Haugvik S-P; Janson ET; Österlund P; Langer SW; Falk RS; Labori KJ; Vestermark LW; Grønbæk H; Gladhaug IP; Sorbye H
Article: SUPPORTIVE CARE IN CANCER. 2015;23(6):1495-1502

NRS-2002 for pre-treatment nutritional risk screening and nutritional status assessment in head and neck cancer patients.

Orell-Kotikangas H; Österlund P; Saarilahti K; Ravasco P; Schwab U; Mäkitie AA
Article: LANCET ONCOLOGY. 2015;16(5):499-508

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.

Tabernero J; Yoshino T; Cohn AL; Obermannova R; Bodoky G; Garcia-Carbonero R; Ciuleanu T-E; Portnoy DC; Van Cutsem E; Grothey A; Prausová J; Garcia-Alfonso P; Yamazaki K; Clingan PR; Lonardi S; Kim TW; Simms L; Chang S-C; Nasroulah F; RAISE Study Investigators
Article: EUROPEAN JOURNAL OF CANCER. 2014;50(17):2966-2974

Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?

Soveri LM; Hermunen K; de Gramont A; Poussa T; Quinaux E; Bono P; André T; Österlund P
Article: NEUROGASTROENTEROLOGY AND MOTILITY. 2014;26(8):1179-1187

Deoxycholic acid induced changes in electrophysiological parameters and macromolecular permeability in murine small intestine with and without functional enteric nervous system plexuses.

Forsgård RA; Korpela R; Stenman LK; Osterlund P; Holma R
Article: CLINICAL CANCER RESEARCH. 2014;20(12):3338-3347

Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.

Manceau G; Imbeaud S; Thiébaut R; Liébaert F; Fontaine K; Rousseau F; Génin B; Le Corre D; Didelot A; Vincent M; Bachet J-B; Chibaudel B; Bouché O; Landi B; Bibeau F; Leroy K; Penault-Llorca F; Van Laethem J-L; Demetter P; Tejpar S; Rossi S; Mosakhani N; Osterlund P; Ristamäki R; Sarhadi V; Knuutila S; Boige V; André T; Laurent-Puig P
Article: ONCOLOGY LETTERS. 2014;7(2):553-559

Helicobacter pylori and gastrointestinal symptoms in diagnostics and adjuvant chemotherapy of colorectal cancer.

Soveri L-M; Osterlund P; Ruotsalainen T; Poussa T; Rautelin H; Bono P
Article: ONCOTARGETS AND THERAPY. 2014;7:1177-1184

A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection.

Osterlund P; Peltonen R; Alanko T; Bono P; Isoniemi H
Article: PLOS ONE. 2014;9(6):e99590

Heterogeneous EGFR gene copy number increase is common in colorectal cancer and defines response to anti-EGFR therapy.

Ålgars A; Avoranta T; Österlund P; Lintunen M; Sundström J; Jokilehto T; Ristimäki A; Ristamäki R; Carpén O
Article: ANTICANCER RESEARCH. 2013;33(1):253-260

CEA fluctuation during a single fluorouracil-based chemotherapy cycle for metastatic colorectal cancer.

Hermunen K; Haglund C; Osterlund P
Article: ANNALS OF ONCOLOGY. 2013;24(1):152-160

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.

Sorbye H; Welin S; Langer SW; Vestermark LW; Holt N; Osterlund P; Dueland S; Hofsli E; Guren MG; Ohrling K; Birkemeyer E; Thiis-Evensen E; Biagini M; Gronbaek H; Soveri LM; Olsen IH; Federspiel B; Assmus J; Janson ET; Knigge U
Article: JOURNAL OF CLINICAL GASTROENTEROLOGY. 2013;47(1):45-51

Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer.

Holma R; Korpela R; Sairanen U; Blom M; Rautio M; Poussa T; Saxelin M; Osterlund P
Article: LANCET ONCOLOGY. 2013;14(1):29-37

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

Bennouna J; Sastre J; Arnold D; Österlund P; Greil R; Van Cutsem E; von Moos R; Viéitez JM; Bouché O; Borg C; Steffens C-C; Alonso-Orduña V; Schlichting C; Reyes-Rivera I; Bendahmane B; André T; Kubicka S; ML18147 Study Investigators
Article: CANCER GENETICS. 2012;205(11):545-551

MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.

Mosakhani N; Lahti L; Borze I; Karjalainen-Lindsberg M-L; Sundström J; Ristamäki R; Osterlund P; Knuutila S; Sarhadi VK
Article: HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK. 2012;34(10):1450-1455

High prevalence of vitamin D insufficiency in patients with head and neck cancer at diagnosis.

Orell-Kotikangas H; Schwab U; Österlund P; Saarilahti K; Mäkitie O; Mäkitie AA
Article: INTERNATIONAL JOURNAL OF COLORECTAL DISEASE. 2012;27(2):171-178

Colonic methanogenesis in vivo and in vitro and fecal pH after resection of colorectal cancer and in healthy intact colon.

Holma R; Osterlund P; Sairanen U; Blom M; Rautio M; Korpela R
Article: SCANDINAVIAN JOURNAL OF SURGERY. 2012;101(4):275-282

Does preoperative radiotherapy with postoperative chemotherapy increase acute side-effects and postoperative complications of total mesorectal excision? Report of the randomized Finnish rectal cancer trial.

Salmenkylä S; Kouri M; Österlund P; Pukkala E; Luukkonen P; Hyöty M; Pääkkönen M; Mäkelä J; Mustonen H; Järvinen HJ; Finnish Rectal Cancer Trial Group
Article: GENES CHROMOSOMES & CANCER. 2012;51(1):1-9

MicroRNA profiling differentiates colorectal cancer according to KRAS status.

Mosakhani N; Sarhadi VK; Borze I; Karjalainen-Lindsberg M-L; Sundström J; Ristamäki R; Osterlund P; Knuutila S
Article: BRITISH JOURNAL OF CANCER. 2011;104(4):599-604

Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy.

Österlund P; Soveri L-M; Isoniemi H; Poussa T; Alanko T; Bono P
Article: INTERNATIONAL JOURNAL OF CANCER. 2007;121(9):2052-2059

Temporal trends in the proportion cured for cancer of the colon and rectum: a population-based study using data from the Finnish Cancer Registry.

Lambert PC; Dickman PW; Österlund P; Andersson T; Sankila R; Glimelius B
Article: BRITISH JOURNAL OF CANCER. 2007;97(8):1028-1034

Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study.

Osterlund P; Ruotsalainen T; Korpela R; Saxelin M; Ollus A; Valta P; Kouri M; Elomaa I; Joensuu H
Article: ACTA ONCOLOGICA. 2005;44(3):203-217

Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report.

Nygren P; Sørbye H; Osterlund P; Pfeiffer P
Article: CLINICAL GASTROENTEROLOGY AND HEPATOLOGY. 2004;2(8):696-703

Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer.

Osterlund P; Ruotsalainen T; Peuhkuri K; Korpela R; Ollus A; Ikonen M; Joensuu H; Elomaa I
Article: BRITISH JOURNAL OF CANCER. 2002;87(6):591-599

Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.

Osterlund P; Orpana A; Elomaa I; Repo H; Joensuu H
Article: ONCOLOGY. 2001;61(2):113-119

A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer.

Osterlund P; Elomaa I; Virkkunen P; Joensuu H
Visa fler

Alla övriga publikationer

Letter: JOURNAL OF GERIATRIC ONCOLOGY. 2024;15(2):101632

The effect of BRAFV600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer - A post-hoc exploratory analysis of the randomized NORDIC9-study.

Liposits G; Winther SB; Ryg J; Skuladottir H; Möller S; Hofsli E; Shah C-H; Poulsen LØ; Berglund Å; Qvortrup C; Osterlund P; Glimelius B; Sorbye H; Pfeiffer P
Corrigendum: CLINICAL NUTRITION ESPEN. 2023;58:421-423

Corrigendum to "Time to act! - A cross-sectional study on how nutritional risk increases during hospitalization and associates with worse" published in Clinical Nutrition ESPEN 2023 Oct;57:364-374.

Orell H; Pohju A; Tuokkola J; Junttila K; Heikkilä A; Österlund P; Schwab U; Mäkitie A
Review: ESMO OPEN. 2023;8(3):101567

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022.

Ducreux M; Abou-Alfa GK; Bekaii-Saab T; Berlin J; Cervantes A; de Baere T; Eng C; Galle P; Gill S; Gruenberger T; Haustermans K; Lamarca A; Laurent-Puig P; Llovet JM; Lordick F; Macarulla T; Mukherji D; Muro K; Obermannova R; O'Connor J-M; O'Reilly EM; Osterlund P; Philip P; Prager G; Ruiz-Garcia E; Sangro B; Seufferlein T; Tabernero J; Verslype C; Wasan H; Van Cutsem E
Other: CASE REPORTS IN ONCOLOGY. 2021;14(3):1475-1482

Metastatic Rectal Carcinoma with Long-Term Remission due to Modern Multimodality Treatment.

Eigeliene N; Saarenheimo J; Wichmann V; Österlund P; Jekunen A
Letter: THE LANCET REGIONAL HEALTH - EUROPE. 2021;5:100135

Lung metastasectomy for colorectal cancer in the PulMiCC randomised controlled trial - Authors' reply.

Osterlund P; Isoniemi H
Letter: ACTA ONCOLOGICA. 2020;59(12):1503-1507

An easily adaptable validated risk score predicts cancer-specific survival in stage II colon cancer.

Heervä E; Väliaho V; Salminen T; Nieminen L; Carpelan A; Kurki S; Sundström J; Huhtinen H; Rantala A; Carpén O; Minn H; Österlund P; Ålgars A; Ristamäki R
Editorial comment: SEMINARS IN ONCOLOGY. 2017;44(2):129-131

Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer-A definite conclusion?

Ducreux M; Österlund P; Pignon JP
Letter: JOURNAL OF CLINICAL ONCOLOGY. 2017;35(2):254-255

Global Curriculum Edition 2016: European Society for Medical Oncology/American Society of Clinical Oncology Recommendations for Training in Medical Oncology.

Dittrich C; Kosty MP; Jezdic S; Pyle D; Berardi R; Bergh J; El-Saghir NS; Lotz J-P; Österlund P; Pavlidis N; Purkalne G
Editorial comment: ANNALS OF ONCOLOGY. 2016;27(8):1378-1381

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016.

Dittrich C; Kosty M; Jezdic S; Pyle D; Berardi R; Bergh J; El Saghir N; Lotz J-P; Österlund P; Pavlidis N; Purkalne G; ESMO/ASCO Global Curriculum Working Group
Review: TARGETED ONCOLOGY. 2016;11(3):293-308

A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer.

Loupakis F; Stein A; Ychou M; Hermann F; Salud A; Österlund P
Review: ESMO OPEN. 2016;1(5):e000097

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Dittrich C; Kosty M; Jezdic S; Pyle D; Berardi R; Bergh J; El-Saghir N; Lotz J-P; Österlund P; Pavlidis N; Purkalne G; Awada A; Banerjee S; Bhatia S; Bogaerts J; Buckner J; Cardoso F; Casali P; Chu E; Close JL; Coiffier B; Connolly R; Coupland S; De Petris L; De Santis M; de Vries EGE; Dizon DS; Duff J; Duska LR; Eniu A; Ernstoff M; Felip E; Fey MF; Gilbert J; Girard N; Glaudemans AWJM; Gopalan PK; Grothey A; Hahn SM; Hanna D; Herold C; Herrstedt J; Homicsko K; Jones DV; Jost L; Keilholz U; Khan S; Kiss A; Köhne C-H; Kunstfeld R; Lenz H-J; Lichtman S; Licitra L; Lion T; Litière S; Liu L; Loehrer PJ; Markham MJ; Markman B; Mayerhoefer M; Meran JG; Michielin O; Moser EC; Mountzios G; Moynihan T; Nielsen T; Ohe Y; Öberg K; Palumbo A; Peccatori FA; Pfeilstöcker M; Raut C; Remick SC; Robson M; Rutkowski P; Salgado R; Schapira L; Schernhammer E; Schlumberger M; Schmoll H-J; Schnipper L; Sessa C; Shapiro CL; Steele J; Sternberg CN; Stiefel F; Strasser F; Stupp R; Sullivan R; Tabernero J; Travado L; Verheij M; Voest E; Vokes E; Von Roenn J; Weber JS; Wildiers H; Yarden Y
Editorial comment: ESMO OPEN. 2016;1(1):e000004

The ESMO/ASCO Global Curriculum and the evolution of medical oncology training in Europe.

Pavlidis N; Alba E; Berardi R; Bergh J; El Saghir N; Jassem J; Kosty M; Lopez R; Lotz J-P; Österlund P; Purkalne G; Dittrich C
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(3):520

Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study.

Kubicka S; Greil R; Andre T; Bennouna J; Sastre J; Van Cutsem E; Von Moos R; Osterlund PJ; Hegde P; Sersch MA; Osborne S; Hermann F; Arnold D
Review: SCANDINAVIAN JOURNAL OF SURGERY. 2011;100(1):35-41

Surgery combined with oncological treatments in liver metastases from colorectal cancer.

Isoniemi H; Osterlund P
Letter: ANNALS OF ONCOLOGY. 2009;20(2):393-394

Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma.

Bono P; Elfving H; Utriainen T; Osterlund P; Saarto T; Alanko T; Joensuu H

Om mig

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI